Loading...
Market
How will semaglutide impact cardiovascular events in type 2 diabetics by end of 2025?
2
Resolution / Starting Odds
Significant reduction • 25%
Moderate reduction • 25%
No significant change • 25%
Increase in events • 25%
Results from major clinical trials and studies
Story
Studies Show Semaglutide Benefits for Type 2 Diabetes, Knee Pain Reduction by 50%
Nov 7, 2024, 11:00 AM
Recent studies have highlighted the significant health benefits of semaglutide, a GLP-1 receptor agonist, for adults with type 2 diabetes and other conditions. Semaglutide was found to significantly lower the risk of Alzheimer's disease compared to other antidiabetic medications. Additionally, it reduced kidney and cardiovascular disease events in type 2 diabetics and improved obesity-related heart failure with preserved ejection fraction in a placebo controlled trial. In a post hoc analysis, treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation compared to a placebo. A separate study indicated that weekly self-injections of semaglutide could reduce knee pain from moderate osteoarthritis by nearly 50%.
View original story
Similar markets
Heart Disease • 25%
Stroke • 25%
Chronic Kidney Disease • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Obstructive Sleep Apnea • 25%
Alzheimer's Disease • 25%
Metabolic Liver Dysfunction • 25%
Other • 25%
Diabetic Macular Edema • 25%
Metabolic Liver Dysfunction • 25%
Addiction Treatment • 25%
Other • 25%
Significant improvement • 25%
Moderate improvement • 25%
No change • 25%
Worsening • 25%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
No significant change • 25%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Significant reduction • 25%
Moderate reduction • 25%
No change • 25%
Increase • 25%
No new data released • 25%
Reduction below 20% • 25%
Reduction between 20% and 30% • 25%
Reduction above 30% • 25%